Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

Inclusion Criteria: * written informed concent * age \> or equal 18 years * able to comply with the protocol * histologically or cytologically confirmed, Her-2 negative, adenocarcinoma of the breast with measurable or nonmeasurable metastatic disease, chemotherapy indicated * ECOG 0-2, life expectancy of over or qual to 12 wks * prior neo/adjuvant chemotherapy allowed * prior adjuvant taxane therapy is allowed, DFS\> or equal 6 months * previous hormonal therapy allowed * prior RT is allowed as adjuvant setting or to relief of metastatic bone pain, no more than 30% of marrow-bearing bone irradiated * Adequate haematological function * adequate liver function total bilirubin \<1.5 x upper limit of normal and AST,ALT \<2.5 x ULN in patients without liver metastases; \<5 x ULN in patients with liver metastases * adequate renal function serum creatinine \<or equal 1,5x ULN or calculated creatinine clearance \> or equal 50mL/min and urine dipstick for proteinuria \<2+. Patients discovered to have or equal proteinuria or dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \< or equal 1 g of protein in 24 hours * INR\<or equal 1.5 and PTT\< or equal 1.5 x ULN within 7 days prior to enrolment. Anticoagulation treatment not allowed * if female, should not be pregnant or breast-feeding. Women with an intact uterus must have a negative serum pregnancy test within 28 days prior to inclusion into the study Exclusion Criteria: * previous chemotherapy for mBC * radiation therapy for the treatment of metastatic disease within 28 days * evidence of CNS metastases. If symptomatic, the patient should be scanned within 28 days to enrolment to rule out CNS metastases * pre-existing peripheral neuropathy NCI CTC-AE grade \> 2 at enrolment * major surgery, significant traumatic injury within 28 days prior to enrolment or anticipation of the need for major surgery during study treatment * Minor surgery, including insertion off an indwelling catheter, within 24 hours prior to the first line bevacizumab infusion * Current or recent(within 10 daÿs of first dose of bevacizumab) use of aspirin (\>325mg/day) * current or recent (within 10 days of first dose of bevacizumab) use of oral or parenteral anticoagulants or thrombolytic agents. * history of evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding * uncontrolled hypertension (systolic \>150mmHg and/or diastolic\>100mmHg) * Clinically significant cardiovascular disease for example CVA, myocardial infarction, unstable angina, congestive heart failure NYHA Class \> or equal II, serious cardiac arrhythmia requiring medication during the study, which might interfere with regularity of the study treatment, or not controlled by medication * non- healing wound, active peptic ulcer or bone fracture * history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment * past of current history (within the last 5 years) of other malignancies except curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix * treatment with any other investigational agent, or participation in another clinical drug trial within 28 days prior to enrolment * evidence of any other disease, neurological, psychiatric or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications * history of thrombotic disorders within last six months